TP53 and intrahepatic cholangiocarcinoma: As there are few targeted treatments for poorly differentiated ICC, we screened our models driven by KRASG12D-expression and either Tp53 loss, Nf2 loss, or a combination of the two for activated and pharmacologically targetable signaling pathways using highly multiplexed RPPAs.